Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Chemotherapy Induced Febrile Neutropenia
NCT06988826Phase 4Not yet recruiting
- Sponsor
- King Edward Medical University
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons
01
Overview
Phase 4 trial of filgrastim in febrile neutropenia (FN) (2 arms), sponsored by King Edward Medical University. Primary endpoint: Resolution of Febrile Neutropenia at 2 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06988826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988826.